^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

TAVO412

i
Other names: TAVO412, Tavo-412
Associations
Company:
Tavotek
Drug class:
EGFR inhibitor, c-MET inhibitor, VEGF inhibitor
Related drugs:
Associations
23d
A Study of TAVO412 in Patients with Cancer (clinicaltrials.gov)
P1, N=50, Active, not recruiting, Tavotek Biotherapeutics | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Dec 2025
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation
|
TAVO412
over1year
A Study of TAVO412 in Patients With Cancer (clinicaltrials.gov)
P1, N=50, Recruiting, Tavotek Biotherapeutics | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation
|
TAVO412
over1year
A Study of TAVO412 in Patients With Cancer (clinicaltrials.gov)
P1, N=50, Not yet recruiting, Tavotek Biotherapeutics | Initiation date: Jan 2023 --> Apr 2023 | Trial primary completion date: Jan 2024 --> Jun 2024
Trial initiation date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation
|
TAVO412
2years
A Study of TAVO412 in Patients With Cancer (clinicaltrials.gov)
P1, N=50, Not yet recruiting, Tavotek Biotherapeutics
New P1 trial
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation
|
TAVO412